Amycretin vs Pramlintide
GLP-1 and amylin agonism combined in a single molecule, not a two-drug combination. The first amylin analog — native amylin with its self-aggregation edited out. Side by side: type, evidence tier, receptor, molecular weight, and half-life — the same fields as each monograph, rearranged so the engineering difference is visible.
Amycretin | Pramlintide | |
|---|---|---|
| Also known as | — | Symlin |
| Type | Analog | Analog |
| Evidence | Investigational | Established |
| Family | Incretins & metabolic | Incretins & metabolic |
| Class | Unimolecular GLP-1 + amylin receptor agonist (peptide) | Amylin analog (synthetic 37 aa peptide) |
| Receptor | GLP-1 receptor + amylin receptors | Amylin receptors (calcitonin receptor + RAMP) |
| Molecular weight | ≈7,900 Da | ~3,949.4 Da |
| Half-life | ~days (weekly SC dosing) | |
| Based on | Amylin | Amylin |
Half-life bars are on a logarithmic scale across the molecules shown. Reference values for the native or representative form — educational only, not medical or dosing advice.
Common questions
- What is the difference between Amycretin and Pramlintide?
- Amycretin is an engineered analog based on Amylin; Pramlintide is an engineered analog based on Amylin. Amycretin signals at GLP-1 receptor + amylin receptors; Pramlintide signals at Amylin receptors (calcitonin receptor + RAMP).
- How do the half-lives of Amycretin and Pramlintide compare?
- The reported circulating half-life of Amycretin is ~days (weekly SC dosing); Pramlintide is ~48 min. These are reference values for the native or representative form — educational only, not dosing advice.
Prefer the other order? Pramlintide vs Amycretin. Or open the interactive comparison tool to add more molecules.